Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration

PURPOSE: To compare the efficacy and safety of 1.25 mg versus 2.5 mg intravitreal bevacizumab (IVB) for treatment of choroidal neovascularization (CNV) associated with agerelated macular degeneration (AMD). METHODS: In this randomized clinical trial, consecutive patients with active CNV associated w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Modarreszadeh, Mehdi, Naseripour, Masood, Ghasemi-Falavarjani, Khalil, Nikeghbali, Aminollah, Hashemi, Masih, Parvaresh, Mohammad-Mehdi
Médium: Artigo
Jazyk:Inglês
Vydáno: Ophthalmic Research Center 2008
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3589230/
https://ncbi.nlm.nih.gov/pubmed/23479531
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky